- Shares of Celgene (CELG -1.3%) are on the move as the company presents at the JPMorgan Healthcare Conference.
- The stock initially spiked as the company updated its guidance, but the shares have since reversed course.
- 2013 adjusted EPS: $5.96 versus consensus of $6.
- Revlimid: 2013 sales, $4.28B (+14% Y/Y); 2017 guidance, $7B (+$1B from previous).
- Pomalyst: 2017 sales guidance, $1.5B.
- 2017 EPS guidance: "At least $15" versus previous guidance of $13-14.
- 2017 revenue guidance: $13-14B (up from $12B).
- Presentation is here.